Obesity drug has no competitors on unexploited market, says Novo Nordisk

Executive Vice President cannot see any drug currently on the market that can compete with Novo Nordisk's recently approved Wegovy – but the company is still keeping its foot on the gas and launching quickly.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT

It isn't pressure from competitors that is making Novo Nordisk aim for "the fastest launch after approval ever" for its new drug Wegovy, which was approved by the FDA on Friday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms